Replies to post #205095 on Anavex Life Sciences Corp (AVXL)

[seventhwave]

So are you dissing A2-73 for it's inability to maintain or increase these cognitive measures. While there may be 5-10% super-responders, expecting it across the tested population an unrealistic expectation that no one on this board harbors.
The A2-73 p2b trial *WILL* show an identifiable differentiation. The question is one of magnitude of differentiation and statistical significance.
Remember, the bar for success is super low as nothing really works currently.
Yes, a lower degree of demonstrated differentiation will result in low gains in SP initially, its safety will ensure it will be the go-to solution for all globally and SP gains will follow prescription growth to our desired SP potential.

[sokol]

No patient taking any drug is going to stay the same and/or get better with time. Furthermore, none of us will remain the same, and we will all decline as time goes by whether we take prescription drugs or not. We are all going to demise and die at some point. But, to put this in another perspective, cancer drugs are approved that merely extend a patient’s life for a matter of months. This will be my last post for the near future. I will not read or reply to any replies. Have a good day, a good remainder of the summer, and good luck, etc., etc.